Abstract
Hexadecylphosphocholine, INN: Miltefosine (Figure 1), the lead compound of the alkylphosphocholines, has shown its antineoplastic activity in various in-vitro and in-vivo tumor models (Hilgard et al. 1993). After oral administration to patients miltefosine induced a remarkable leucocytosis (Pronk et al. 1994). This suggested a stimulatory effect of the compound on the hematopoietic system. To investigate this phenomenon, mouse and rat bone marrow was stimulated with either recombinant mouse/rat IL-3 or mouse GM-CSF with or without the addition of miltefosine. Additionally, Northern blot analysis was performed on human myeloid leukemic cell lines for the IL-3 and GM-CSF receptor genes and for TNFα mRNA on peripheral blood cells stimulated with concanavalin A (Con A) or lipopolysaccharid (LPS) when they were exposed to Miltefosine.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Baier JE, Brauckmann-Berger JM, Neumann HA (1995) Modulatorische Eigenschaft des Alkyllysophospholipids Ilmofosin auf Zytokine. Tumordiagn. u. Ther. 16, 88–93
Beckers T, Voegeli R, Hilgard P (1994) Molecular and cellular effects of Hexadecylphosphocholine (Miltefosine) in human myeloid leukemic cell lines. Eur. J. Cancer 30A (14), 2143–2150
Berger MR, Yanapirut P, Reinhardt M, Klenner T, Scherf HR, Schmeiser HH, Eibl H (1992) Antitumor activity of Alkylphosphocholines and analogues in methylnitrosourea-induced rat mammary carcinomas. In: Eibl H, Hilgard P, Unger C (eds): Alkylphosphocholines: New drugs in Cancer Therapy. Prog Exp Tumor Res. Basel, Karger, Vol. 34, 98–115
Harlemann J (1994) Tumor differentiation in-vivo with Miltefosine. In: Drugs of Today, Clinical aspects of milte- fosine and ist topical formulation Miltex® Ed: Hilgard P, Engel J, Vol. 30, Suppl. B, 43–46
Hilgard P, Klenner T, Stekar J, Unger C (1993) Alkylphosphocholines: A new class of membrane-active anticancer agents. Cancer Chemother Pharmacol 32, 90–95
Holtmann H, Hahn T, Wallach D (1988) Immunobiol. 177, 7–22
Kitamura T, Sato N, Arai K, Miyajima A. Expression cloning of the human IL-3 receptor cDNA reveals a shared ß-subunit for the human IL-3 and GM-CSF receptors. Cell 1991, 66, 1165–1174
Nooter K, Stoter G, Verweij J (1994) Induction of hematopoietic differentiation by the alkylphosphocholine Miltefosine. In: Drugs of Today, Clinical aspects of miltefosine and ist topical formulation Miltex® Ed: Hilgard P, Engel J. Vol. 30, Suppl. B, 31–42
Pronk LC, Planting ASTh, Oosterom R, Drogendijk TE, Stoter G, Verweij J (1994) Increases in leucocyte and platelet counts induced by the alkylphospholipid hexadecylphosphocholine. Eur. J. Cancer, 30A (7), 1019–22
Überall F, Oberhuber H, Maly K, Zaknun J, Demuth L, Grunicke HH (1991) Hexadecylphosphocholine inhibits inositol phosphate formation and proteinkinase C activity. Cancer Res. 51, 807–812
Winzen R, Wallach D, Kemper O, Resch K, Holtmann H (1993) J. Immunol. 150, 4346–4353
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Klenner, T., Beckers, T., Nooter, K., Holtmann, H. (1996). Influence of Hexadecylphosphocholine (Miltefosine) on Cytokine Synthesis and Biological Responses. In: Nigam, S., Kunkel, G., Prescott, S.M. (eds) Platelet-Activating Factor and Related Lipid Mediators 2. Advances in Experimental Medicine and Biology, vol 416. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0179-8_30
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0179-8_30
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0181-1
Online ISBN: 978-1-4899-0179-8
eBook Packages: Springer Book Archive